Effect of continuous glucose monitoring on time to diagnosis among patients with heart failure
Published
July 23, 2026
Paper ID
PAP-000111
Status
Published
DOI
10.65712/tmj.test000369
Advance Services
Abstract
Background: Practice around continuous glucose monitoring varies widely between centres. Methods: Eligible participants were patients with heart failure. Results: time to diagnosis occurred in 14% of the intervention group versus 12% of controls. The adjusted odds ratio was 0.55 (95% CI 0.46 to 0.70). Conclusion: These findings suggest that continuous glucose monitoring is associated with better time to diagnosis in patients with heart failure.
Introduction
Earlier studies of continuous glucose monitoring were small or single-centre.
Earlier studies of continuous glucose monitoring were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among patients with heart failure. The cost of time to diagnosis to health systems is substantial.
Practice around continuous glucose monitoring varies widely between centres.
Materials and Methods
Missing data were handled with multiple imputation. The primary outcome was time to diagnosis, assessed blind to allocation. We conducted a pilot feasibility study across 5 centres between 2014 and 2025.
The primary outcome was time to diagnosis, assessed blind to allocation.
Missing data were handled with multiple imputation. The primary outcome was time to diagnosis, assessed blind to allocation.
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Results
The adjusted odds ratio was 0.48 (95% CI 0.23 to 0.76). 1573 participants were included (median age 55 years).
| Group | n | Events |
|---|---|---|
| Control | 65 | 3 |
| Centre A | 738 | 81 |
| Centre B | 511 | 72 |
| Intervention | 861 | 85 |
| Centre A | 666 | 24 |
| Female | 722 | 85 |
| Age ≥ 65 | 358 | 22 |
Values are n (%) unless stated otherwise.

Shown for patients with heart failure; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. time to diagnosis occurred in 15% of the intervention group versus 24% of controls.
1565 participants were included (median age 67 years). time to diagnosis occurred in 9% of the intervention group versus 38% of controls. 3558 participants were included (median age 68 years).
Discussion
Implementation will depend on staffing, cost and local protocols.
Implementation will depend on staffing, cost and local protocols. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.
Implementation will depend on staffing, cost and local protocols. These findings suggest that continuous glucose monitoring is associated with better time to diagnosis in patients with heart failure. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols.
Conclusions
Continuous glucose monitoring should be considered for patients with heart failure to improve time to diagnosis.
References
1. Farouk N, Moreau E, et al. An antibiotic stewardship programme and in-hospital mortality. N Engl J Med. 2019;66(3):260-1378.
2. Kaur T, Silva J, et al. Home-based cardiac rehabilitation and 30-day readmission. Diabetes Care. 2010;21(4):867-1539.
3. Okafor W, Novak A, et al. Nurse-led discharge planning and patient satisfaction. Lancet. 2010;202(6):572-1042.
4. Mueller H, Novak K, et al. A sepsis alert system and falls. Ann Intern Med. 2016;278(9):171-1606.
5. Okafor V, Patel T, et al. High-flow nasal oxygen and patient satisfaction. N Engl J Med. 2013;166(11):521-1398.
6. Silva T, Dubois F, et al. Early enteral nutrition and health-related quality of life. BMC Med. 2008;212(7):18-1234.
Appendices
Ethics approval: IRB-2076.